Abstract | PURPOSE: METHODS: RESULTS: In both eyes, there were no changes detected in the arteriovenous transit time or peripheral capillary nonperfusion after anti- VEGF therapy. A reduction in intraretinal hemorrhages and nerve fiber layer infarcts was observed at 7 days and 35 days after treatment in the patient with CRVO and at 30 days after treatment in the patient with BRVO. A decrease in vessel caliber was observed at 7 days after treatment in the patient with CRVO and at 30 days after treatment in the patient with BRVO. In the patient with CRVO, an increase in vessel caliber with a recurrence of vascular leakage was noted at the visit on Day 35. CONCLUSION: Anti- VEGF therapy in the setting of RVO may initially decrease vessel caliber, retinal hemorrhages, and nerve fiber layer infarcts but does not appear to affect arteriovenous transit time or areas of peripheral capillary nonperfusion after a single treatment. The beneficial effects of anti- VEGF therapy in RVO appear transient, and multiple injections may be required for control of macular edema. Ultra wide-field angiography can be a useful tool in monitoring the treatment of RVO.
|
Authors | Sushma K Vance, Louis K Chang, Yutaka Imamura, K Bailey Freund |
Journal | Retinal cases & brief reports
(Retin Cases Brief Rep)
Vol. 5
Issue 4
Pg. 343-7
( 2011)
ISSN: 1935-1089 [Print] United States |
PMID | 25390431
(Publication Type: Journal Article)
|